Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

The ability of cancer to evolve and adapt is a principal challenge to therapy in general and to
the paradigm of targeted therapy in particular. This ability is fueled by the co-existence of …

The mechanisms involved in the progression from monoclonal gammopathy of
undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple …

Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the
clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal …

The treatment outcome of multiple myeloma (MM) is worse than expected from the average
numbers of non-synonymous mutations, which are roughly correlated with the prognosis of …

Multiple myeloma (MM) is a plasma cell cancer with poor survival, characterized by the
expansion of multiple myeloma cells (MMCs) in the bone marrow. Using a microarray-based …

Achieving complete remission (CR) in multiple myeloma (MM) translates into extended
survival, but two subgroups of patients fall outside this paradigm: cases with unsustained …

In spite of significant advances in the management of multiple myeloma (MM), the disease
remains incurable and nearly all patients ultimately relapse and require salvage …

Single-cell analysis is of significant importance in delineating the exact phylogeny of the
subclonal population and in discovering subtle diversification. So far, studies of intratumor …

Every day, cells are faced with thousands of DNA lesions, which have to be repaired to
preserve cell survival and function. DNA repair is more or less accurate and could result in …